Skip to content

Study · Randomized controlled trial · n = 36 · 2015

7 results

Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.

Cerit H, Veer IM, Dahan A, Niesters M, Harmer CJ, Miskowiak KW, Rombouts SA, Van der Does W

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology18 Sept 2015Cited by 9 (Europe PMC)

PMID26431906 (opens in a new tab)DOI10.1016/j.euroneuro.2015.09.005 (opens in a new tab)PepBankPUB-26431906
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy adults, ARA290 2 mg lowered neural responses to happy faces in the fusiform gyrus one week after administration compared with placebo.

    In plain wordsIn healthy adults, one week after ARA290, brain responses to happy faces were lower than with placebo.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseNeural response to happy faces in the fusiform gyrus
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2 mgAs given in this study (human).

    Source sentences

    Summary
    ARA290-treated individuals displayed lower neural responses to happy faces in the fusiform gyrus.
    2 context sentences
    Summary · context
    Healthy participants (N=36) received ARA290 (2mg) or placebo in a double-blind, randomized, parallel-group design.
    Summary · context
    Neural and cognitive effects were assessed one week after administration.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy adults, ARA290 tended to lower recognition of happy facial expressions compared with placebo; the abstract does not report a significant effect.

    In plain wordsIn healthy adults, ARA290 tended to lower recognition of happy faces compared with placebo, but the result was only a trend.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeBehavioral recognition of happy facial expressions
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2 mgAs given in this study (human).

    Source sentences

    Summary
    ARA290 tended to lower the recognition of happy and disgust facial expressions.
    2 context sentences
    Summary · context
    Healthy participants (N=36) received ARA290 (2mg) or placebo in a double-blind, randomized, parallel-group design.
    Summary · context
    Neural and cognitive effects were assessed one week after administration.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy adults, ARA290 tended to lower recognition of disgust facial expressions compared with placebo; the abstract does not report a significant effect.

    In plain wordsIn healthy adults, ARA290 tended to lower recognition of disgust faces compared with placebo, but the result was only a trend.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeBehavioral recognition of disgust facial expressions
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2 mgAs given in this study (human).

    Source sentences

    Summary
    ARA290 tended to lower the recognition of happy and disgust facial expressions.
    2 context sentences
    Summary · context
    Healthy participants (N=36) received ARA290 (2mg) or placebo in a double-blind, randomized, parallel-group design.
    Summary · context
    Neural and cognitive effects were assessed one week after administration.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy adults, ARA290 was not associated with better memory for positive words compared with placebo.

    In plain wordsIn healthy adults, ARA290 did not improve memory for positive words compared with placebo.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeMemory for positive words
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2 mgAs given in this study (human).

    Source sentences

    Summary
    ARA290 was not associated with a better memory for positive words, it was associated with faster categorization of positive vs negative words.
    2 context sentences
    Summary · context
    Healthy participants (N=36) received ARA290 (2mg) or placebo in a double-blind, randomized, parallel-group design.
    Summary · context
    Neural and cognitive effects were assessed one week after administration.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy adults, ARA290 was associated with faster categorization of positive versus negative words compared with placebo.

    In plain wordsIn healthy adults, ARA290 was linked to faster sorting of positive and negative words than placebo.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseSpeed of categorization of positive vs negative words
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2 mgAs given in this study (human).

    Source sentences

    Summary
    it was associated with faster categorization of positive vs negative words.
    2 context sentences
    Summary · context
    Healthy participants (N=36) received ARA290 (2mg) or placebo in a double-blind, randomized, parallel-group design.
    Summary · context
    Neural and cognitive effects were assessed one week after administration.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy adults, ARA290 increased attention towards positive emotional pictures compared with placebo.

    In plain wordsIn healthy adults, ARA290 increased attention to positive pictures compared with placebo.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseAttention towards positive emotional pictures
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    2 mgAs given in this study (human).

    Source sentences

    Summary
    Finally, ARA290 increased attention towards positive emotional pictures.
    2 context sentences
    Summary · context
    Healthy participants (N=36) received ARA290 (2mg) or placebo in a double-blind, randomized, parallel-group design.
    Summary · context
    Neural and cognitive effects were assessed one week after administration.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In healthy adults, ARA290 had no effect on mood and affective symptoms compared with placebo.

    In plain wordsIn healthy adults, ARA290 did not change mood or emotional symptoms compared with placebo.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    No significant changeMood and affective symptoms
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2 mgAs given in this study (human).

    Source sentences

    Summary
    No effects were observed on mood and affective symptoms.
    2 context sentences
    Summary · context
    Healthy participants (N=36) received ARA290 (2mg) or placebo in a double-blind, randomized, parallel-group design.
    Summary · context
    Neural and cognitive effects were assessed one week after administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1/2NCT02070783

Cognitive and Neural Effects of ARA290

Leiden University Medical Centern = 36Feb 2012 to Feb 2014

Depression

Trial pageClinicalTrials.govUpdated 25 Feb 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.